Baird Capital's Venture Team Leads $12.8MM Series B Investment in Saranas
HOUSTON – July 19, 2021 –Today, Saranas, Inc. announced a $12.8 million Series B investment led by Baird Capital, the venture capital and global private equity arm of Baird. Baird Capital was joined in the investment by Austin, Texas-based S3 Ventures.
Saranas is a privately held medical device company focusing on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented Early Bird® Bleed Monitoring System (“Early Bird”) for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeds immediately before they become complications, improving patient outcomes and lowering healthcare costs. The Early Bird remains the first and only device of its kind.
“We are pleased to announce this round of funding led by Baird Capital,” said Saranas President and CEO James Reinstein. “It underscores the importance of real-time monitoring of bleeding complications and our opportunity to accelerate the commercialization of Early Bird. We look forward to expanding our clinical evidence through prospective clinical trials and launching next generation products, including Bird on a Wire, to address a much broader range of endovascular procedures.”
“As the Saranas team will say, ‘Bleeding happens, but complications don’t have to,’” said Amy Len Kobe, Principal with Baird Capital. “Baird Capital is proud to partner with Saranas to address bleeding complication challenges and provide solutions that improve outcomes and reduce costs for patients, physicians and providers. We are also pleased to invest in Houston, a growing ecosystem of healthcare innovation and a target market for Baird.”
“S3 is enthusiastic about Saranas’ game-changing medical device advancements,” said Brian R. Smith, Managing Director, S3 Ventures. “We invest in companies that are re-imagining the way the world works, lives and heals, and we believe Saranas is a perfect representation of this.”
Baird has been committed to growing its presence in Texas since opening the first office in 1985. In 2018, Baird Capital announced a strategic partnership with the Texas Medical Center (TMC) in Houston, a world leader in collaborative medicine and research. The Baird Capital-TMC partnership remains significant as it continues to bring deep venture expertise in healthcare and technology as well as access to capital to Houston.
For more information on Baird Capital and its venture capital team, please visit BairdCapital.com.
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, please visit www.saranas.com.
About The Early Bird® Bleed Monitoring System
The Early Bird® Bleed Monitoring System includes a Bleed Detection Array with integrated electrodes in a fully functional vascular access sheath. The Early Bird is designed to measure changes in bioimpedance to detect and monitor bleeding from vessel injury during endovascular procedures, such as a transcatheter aortic valve replacement (TAVR), hemodynamic support device placement, or other complex endovascular interventions, where the femoral artery or vein is used to obtain vascular access. Visual and audible indicators on the Early Bird notify the clinician of the onset and progression of bleeding events.
About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 320 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit BairdCapital.com.
About S3 Ventures
Based in Austin, S3 Ventures is the largest venture capital firm focused on Texas. Backed by a philanthropic, multi-billion-dollar family for over fourteen years, S3 Ventures empowers great entrepreneurs with the patient capital and true resources required to grow extraordinary, high-impact companies in Business Technology, Consumer Digital Experiences, and Healthcare Technology. With more than half-a-billion dollars in assets under management, S3 Ventures leads Seed, Series A, and Series B investments with the capacity to follow-on for the life of a company.
For additional information, contact:
Baird Public Relations
Goose Capital, Inc. is an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs. Membership in Goose Capital is limited to executives who have founded or run major enterprises and who are willing to invest in and mentor early stage companies. Goose Capital primarily invests in early-stage companies with proprietary and disruptive technology, manageable capital needs, large addressable markets, the prospect for high margins and an exit strategy within a five-year time period. It typically invests in convertible debt and Series A preferred stock, although it reserves capital for follow-on investments in its portfolio companies.